BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene TherapyZacks Investment Research • 10/28/25
Compared to Estimates, BioMarin (BMRN) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 10/27/25
BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ETPRNewsWire • 10/22/25
BioMarin: Valuation, Growth, And The Pipeline May Outweigh TransCon Competition And Regulatory RisksSeeking Alpha • 09/30/25
BioMarin Pharmaceutical Inc. (BMRN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/09/25
BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual MeetingPRNewsWire • 09/08/25
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of MetabolismPRNewsWire • 09/06/25
BioMarin Pharmaceutical Inc. (BMRN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)Seeking Alpha • 09/04/25
BioMarin Pharmaceutical Inc. (BMRN) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeeking Alpha • 09/03/25
BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy?Zacks Investment Research • 08/18/25
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-TermZacks Investment Research • 08/12/25
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 ViewZacks Investment Research • 08/05/25
BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 08/04/25
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass EstimatesZacks Investment Research • 08/04/25